{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:13:42Z","timestamp":1779243222292,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroToxicology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.neuro.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:21:17Z","timestamp":1709695277000},"page":"12-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats"],"prefix":"10.1016","volume":"102","author":[{"given":"Raj","family":"Katariya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartikey","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivkumar","family":"Sammeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Umekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandkishor","family":"Kotagale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brijesh","family":"Taksande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuro.2024.03.002_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/fcp.12034","article-title":"Participation of central imidazoline binding sites in antinociceptive effect of ethanol and nicotine in rats","volume":"28","author":"Aglawe","year":"2014","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.neuro.2024.03.002_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.brainresbull.2020.11.015","article-title":"Agmatine improves the behavioral and cognitive impairments associated with chronic gestational ethanol exposure in rats","volume":"167","author":"Aglawe","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuro.2024.03.002_bib3","article-title":"Role of agmatine on neuroglia in central nervous system injury","volume":"12","author":"Barua","year":"2018","journal-title":"Brain Neurorehabilitation"},{"issue":"AUG","key":"10.1016\/j.neuro.2024.03.002_bib4","first-page":"254","article-title":"\u2018BDNF signaling and survival of striatal neurons\u2019","volume":"8","author":"Baydyuk","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuro.2024.03.002_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0091-3057(02)01079-1","article-title":"An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine.","volume":"74","author":"Bence","year":"2003","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.neuro.2024.03.002_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49078-0","article-title":"Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate","volume":"9","author":"Bergin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuro.2024.03.002_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112692","article-title":"Neuroprotective action of agmatine in rotenone-induced model of Parkinson's disease: Role of BDNF\/cREB and ERK pathway","volume":"392","author":"Bilge","year":"2020","journal-title":"Behav. Brain Res"},{"issue":"3","key":"10.1016\/j.neuro.2024.03.002_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0149-7634(96)00027-9","article-title":"3-Nitropropionic acid animal model and Huntington\u2019 s disease\u2019","volume":"21","author":"Borlongan","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuro.2024.03.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100130","article-title":"\u2018Neuroprotective effect of silymarin against 3-Nitropropionic acid-induced neurotoxicity in rats\u2019","volume":"3","author":"Chandolia","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.neuro.2024.03.002_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135447","article-title":"Evidences for agmatine alterations in A\u03b21-42 induced memory impairment in mice","volume":"740","author":"Dixit","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuro.2024.03.002_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/jnsbm.JNSBM_239_17","article-title":"Neuroprotective effect of agmatine in mouse spinal cord injury model: Modulation by imidazoline receptors","volume":"9","author":"DIxit","year":"2018","journal-title":"J. Nat. Sci. Biol. Med"},{"key":"10.1016\/j.neuro.2024.03.002_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0197-4580(01)00300-1","article-title":"Phenolic anti-inflammatory antioxidant reversal of A\u03b2-induced cognitive deficits and neuropathology","volume":"22","author":"Frautschy","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuro.2024.03.002_bib13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1007\/s12035-014-8827-1","article-title":"Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line","volume":"51","author":"Freitas","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuro.2024.03.002_bib14","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.euroneuro.2016.10.013","article-title":"Agmatine, a potential novel therapeutic strategy for depression","volume":"26","author":"Freitas","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuro.2024.03.002_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jneumeth.2008.10.011","article-title":"Improved high-performance liquid chromatographic method for GABA and glutamate determination in regions of the rodent brain.","volume":"177","author":"de Freitas Silva","year":"2009","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuro.2024.03.002_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneumeth.2005.06.009","article-title":"ELISA methods to measure cholinergic markers and nerve growth factor receptors in cortex, hippocampus, prefrontal cortex, and basal forebrain from rat brain","volume":"150","author":"Gearhart","year":"2006","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuro.2024.03.002_bib17","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","article-title":"Mechanisms of neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Gil","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuro.2024.03.002_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1460-9568.2006.04590.x","article-title":"Reduced expression of the TrkB receptor in Huntington\u2019s disease mouse models and in human brain","volume":"23","author":"Gin\u00e9s","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuro.2024.03.002_bib19","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2165\/00023210-200721110-00002","article-title":"Agmatine: metabolic pathway and spectrum of activity in brain","volume":"21","author":"Halaris","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuro.2024.03.002_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jns.2013.12.033","article-title":"Docosahexaenoic acid confers enduring neuroprotection in experimental stroke","volume":"338","author":"Hong","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuro.2024.03.002_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11033-018-4501-4","article-title":"The neuroprotective effect of agmatine against amyloid \u03b2-induced apoptosis in primary cultured hippocampal cells involving ERK, Akt\/GSK-3\u03b2, and TNF-\u03b1","volume":"46","author":"Hooshmandi","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuro.2024.03.002_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.physbeh.2015.12.015","article-title":"Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: Possible role of oxidative stress, neuroinflammation, and neurotransmitters","volume":"155","author":"Jamwal","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuro.2024.03.002_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbi.2019.03.001","article-title":"\u2018Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington\u2019s disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors\u2019","volume":"80","author":"Jang","year":"2019","journal-title":"Brain, Behav., Immun."},{"issue":"3","key":"10.1016\/j.neuro.2024.03.002_bib24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1526-4637.2010.00808.x","article-title":"Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial","volume":"11","author":"Keynan","year":"2010","journal-title":"Pain. Med."},{"key":"10.1016\/j.neuro.2024.03.002_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.neuropharm.2006.04.011","article-title":"Participation of alpha-melanocyte stimulating hormone in ethanol-induced anxiolysis and withdrawal anxiety in rats","volume":"51","author":"Kokare","year":"2006","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuro.2024.03.002_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5115\/acb.21.089","article-title":"Role of agmatine in the application of neural progenitor cell in central nervous system diseases: therapeutic potentials and effects","volume":"54","author":"Kosonen","year":"2021","journal-title":"Anat. Cell Biol."},{"key":"10.1016\/j.neuro.2024.03.002_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2020.06.002","article-title":"Involvement of hippocampal agmatine in \u03b21-42 amyloid induced memory impairment, neuroinflammation and BDNF signaling disruption in mice","volume":"80","author":"Kotagale","year":"2020","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.neuro.2024.03.002_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2010.04.049","article-title":"Repeated agmatine treatment attenuates nicotine sensitization in mice: modulation by alpha2- adrenoceptors","volume":"213","author":"Kotagale","year":"2010","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.neuro.2024.03.002_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbr.2014.01.004","article-title":"Agmatine attenuates nicotine-induced conditioned place preference in mice through modulation of neuropeptide Y system","volume":"262","author":"Kotagale","year":"2014","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.neuro.2024.03.002_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuro.2019.05.001","article-title":"Neuroprotective offerings by agmatine","volume":"73","author":"Kotagale","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuro.2024.03.002_bib31","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.neuroscience.2009.01.039","article-title":"Differential effects of i.c.v. microinfusion of agmatine on spatial working and reference memory in the rat","volume":"159","author":"Liu","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuro.2024.03.002_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1017\/S0317167100032212","article-title":"3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin","volume":"18","author":"Ludolph","year":"1991","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuro.2024.03.002_bib33","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1093\/hmg\/ddt203","article-title":"Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington\u2019s disease","volume":"22","author":"Lundh","year":"2013","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.neuro.2024.03.002_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2741\/710","article-title":"Role of agmatine in neurodegenerative diseases and epilepsy","volume":"6","author":"Moretti","year":"2014","journal-title":"Front Biosci. (Elite Ed. )"},{"key":"10.1016\/j.neuro.2024.03.002_bib35","unstructured":"Paxinos, G., Watson, C., Diego, S., Boston, L., York, N., 1997. The Rat Brainin Stereotaxic Coordinates Academic Press."},{"issue":"4","key":"10.1016\/j.neuro.2024.03.002_bib36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1460-9568.2006.04985.x","article-title":"\u2018Hypothalamic\u2013endocrine aspects in Huntington\u2019s disease\u2019","volume":"24","author":"Peters\u00e9n","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuro.2024.03.002_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(79)90366-2","article-title":"Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity","volume":"57","author":"Porsolt","year":"1979","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.neuro.2024.03.002_bib38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s12640-019-00087-x","article-title":"Quality control in Huntington\u2019s disease: A therapeutic target","volume":"36","author":"Rai","year":"2019","journal-title":"Neurotox. Res."},{"issue":"10","key":"10.1016\/j.neuro.2024.03.002_bib39","doi-asserted-by":"crossref","first-page":"284.","DOI":"10.3390\/biomedicines9101284","article-title":"The role of vitamins in neurodegenerative disease: An update","volume":"9","author":"Rai","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.neuro.2024.03.002_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/diseases11030089","article-title":"WNT-\u03b2 Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective","volume":"11","author":"Ramakrishna","year":"2023","journal-title":"Diseases"},{"key":"10.1016\/j.neuro.2024.03.002_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0165-6147(00)01460-7","article-title":"Is agmatine a novel neurotransmitter in brain?","volume":"21","author":"Reis","year":"2000","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.neuro.2024.03.002_bib42","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1124\/jpet.105.086173","article-title":"Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse","volume":"314","author":"Roberts","year":"2005","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neuro.2024.03.002_bib43","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/nu12020576","article-title":"Evidence for dietary agmatine sulfate effectiveness in neuropathies associated with painful small fiber neuropathy. A pilot open-label consecutive case series study","volume":"12","author":"Rosenberg","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.neuro.2024.03.002_bib44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.neuint.2010.07.005","article-title":"\u2018Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system\u2019","volume":"57","author":"Sandhir","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuro.2024.03.002_bib45","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.neuropharm.2005.01.012","article-title":"Mechanisms involved in the antinociception caused by agmatine in mice.","volume":"48","author":"Santos","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuro.2024.03.002_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12035-015-9674-4","article-title":"Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer\u2019s Disease","volume":"54","author":"Saul","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuro.2024.03.002_bib47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10787-022-00935-x","article-title":"Recombinant human erythropoietin and interferon-\u03b2-1b protect against 3-nitropropionic acid-induced neurotoxicity in rats: possible role of JAK\/STAT signaling pathway","volume":"30","author":"Sayed","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"11","key":"10.1016\/j.neuro.2024.03.002_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0293660","article-title":"\u2018Effect of safranal or candesartan on 3-nitropropionicacid-induced biochemical, behavioral and histological alterations in a rat model of Huntington\u2019s disease\u2019","volume":"18","author":"Shehata","year":"2023","journal-title":"PLOS ONE"},{"issue":"2","key":"10.1016\/j.neuro.2024.03.002_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1601-5215.2012.00675.x","article-title":"The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study","volume":"25","author":"Shopsin","year":"2013","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.neuro.2024.03.002_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neuroscience.2006.01.045","article-title":"Histamine improves rat rota-rod and balance beam performances through H(2) receptors in the cerebellar interpositus nucleus","volume":"140","author":"Song","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuro.2024.03.002_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12031-018-1168-1","article-title":"Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats","volume":"66","author":"Sumathi","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuro.2024.03.002_bib52","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.neuro.2024.03.002_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","article-title":"Antidepressant-like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine","volume":"57","author":"Taksande","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuro.2024.03.002_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2010.03.058","article-title":"Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats","volume":"637","author":"Taksande","year":"2010","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.neuro.2024.03.002_bib55","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1476-5381.2011.01484.x","article-title":"Agmatine in the hypothalamic paraventricular nucleus stimulates feeding in rats: involvement of neuropeptide Y","volume":"164","author":"Taksande","year":"2011","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.neuro.2024.03.002_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejphar.2013.10.041","article-title":"Agmatine attenuates chronic unpredictable mild stress induced behavioral alteration in mice","volume":"720","author":"Taksande","year":"2013","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.neuro.2024.03.002_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172779","article-title":"Agmatine reverses ethanol consumption in rats: Evidences for an interaction with imidazoline receptors","volume":"186","author":"Taksande","year":"2019","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.neuro.2024.03.002_bib58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/acer.13972","article-title":"Agmatine inhibits behavioral sensitization to ethanol through imidazoline receptors","volume":"43","author":"Taksande","year":"2019","journal-title":"Alcohol Clin. Exp. Res"},{"issue":"2","key":"10.1016\/j.neuro.2024.03.002_bib59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/molecules15020878","article-title":"3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington\u2019s disease: past, present and future","volume":"15","author":"T\u00fanez","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.neuro.2024.03.002_bib60","first-page":"245","volume":"28","author":"Unal","year":"2018","journal-title":"Agmatine-attenuated Cogn. Soc. deficits subchronic MK-801 Model Schizophr. Rats."},{"key":"10.1016\/j.neuro.2024.03.002_bib61","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.neurobiolaging.2014.05.031","article-title":"Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer\u2019s disease","volume":"35","author":"Vermeiren","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuro.2024.03.002_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.yhbeh.2023.105361","article-title":"Agmatine prevents the manifestation of impulsive burying and depression-like behaviour in progesterone-withdrawn female rats","volume":"152","author":"Vinchurney","year":"2023","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuro.2024.03.002_bib63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","article-title":"Huntington\u2019s disease - neuropathology","volume":"100","author":"Vonsattel","year":"2011","journal-title":"Handb. Clin. Neurol."},{"issue":"11","key":"10.1016\/j.neuro.2024.03.002_bib64","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jne.12190","article-title":"\u2018Hypothalamic Alterations in Huntington\u2019s Disease Patients: Comparison with Genetic Rodent Models\u2019","volume":"26","author":"Wamelen","year":"2014","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.neuro.2024.03.002_bib65","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1474-4422(20)30343-4","article-title":"Interrupting sequence variants and age of onset in Huntington\u2019s disease: clinical implications and emerging therapies.","volume":"19","author":"Wright","year":"2020","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.neuro.2024.03.002_bib66","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2174\/1570159X15666170808120633","article-title":"Neuroprotective Role of Agmatine in Neurological Diseases","volume":"16","author":"Xu","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuro.2024.03.002_bib67","doi-asserted-by":"crossref","first-page":"15426","DOI":"10.1523\/JNEUROSCI.1148-12.2012","article-title":"A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease","volume":"32","author":"Yu-Taeger","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuro.2024.03.002_bib68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."}],"container-title":["NeuroToxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161813X24000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161813X24000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:12:41Z","timestamp":1716941561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161813X24000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":68,"alternative-id":["S0161813X24000226"],"URL":"https:\/\/doi.org\/10.1016\/j.neuro.2024.03.002","relation":{},"ISSN":["0161-813X"],"issn-type":[{"value":"0161-813X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agmatine mitigates behavioral abnormalities and neurochemical dysregulation associated with 3-Nitropropionic acid-induced Huntington's disease in rats","name":"articletitle","label":"Article Title"},{"value":"NeuroToxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuro.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}